미라 파머슈티컬스(MIRA)는 NAS에 상장된 Healthcare · Drug Manufacturers - General 기업입니다. 현재가 $0.83 (+9.61%), 시가총액 $41.01M.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc.
미라 파머슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
미라 파머슈티컬스의 현재 주가는 $0.83 (+9.61%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
미라 파머슈티컬스의 시가총액은 약 $41.01M입니다.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.